African Union Commission launches Consortium for COVID-19 Vaccine Clinical Trials

Africa CDC [to 11 July 2020]
African Union Commission launches Consortium for COVID-19 Vaccine Clinical Trials
9 July 2020
The African Union Commission has launched a new initiative, the Africa Centres for Disease Control and Prevention (Africa CDC) Consortium for COVID-19 Vaccine Clinical Trial (CONCVACT).
CONCVACT is an outcome of the virtual conference on Africa’s Leadership Role in COVID-19 Vaccine Development and Access held on 24-25 June 2020. The conference was hosted by Africa CDC and presided over by the Chairperson of the African Union, H.E. President Cyril Ramaphosa and the Chairperson of the African Union Commission, H.E. Moussa Faki Mahamat.
“Success in developing and providing access to a safe vaccine requires an innovative and collaborative approach, with significant local manufacturing in Africa. We need to support the contribution of African scientists and healthcare professionals. We need to act with urgency,” said H.E. President Cyril Ramaphosa…
CONCVACT aims to secure more than 10 late stage vaccine clinical trials as early as possible on the continent by bringing together global vaccine developers and funders, as well as African organizations that facilitate clinical trials. The goal is to ensure that sufficient data is generated on the safety and efficacy of the most promising vaccine candidates for the African population so they can be confidently rolled out in Africa once vaccines are approved.
CONCVACT will focus on dismantling the most critical barriers to clinical trials by:
[1] establishing partnerships with leading vaccine developers to host select late-stage trial sites in Africa;
[2] identifying countries and regions where opportunities to conduct trials are most promising (e.g. availability of strong local trial sponsors, good clinical practice investigators, access to granular epidemiologic data, support from regulatory bodies);
[3] setting up an independent review board to provide guidance, assistance and oversight to clinical trials (e.g. regulatory, ethics, safety, etc.);
[4] engaging with African and global media and key opinion leaders on the continent to increase public awareness of the need and importance of hosting well-regulated clinical trials in Africa;
[5] providing objective, fact-based scientific guidance for interpreting the results of clinical trial data;
[6] engaging global donors that are interested in investing in scaling-up vaccine distribution in Africa to raise sufficient funds to support the trials…